Sanofi Pasteur, the manufacturer of the only yellow fever vaccine (YF-VAX) licensed in the United States, has announced that their stock of YF-VAX is totally depleted as of July 24, 2017. YF-VAX for civilian use will be unavailable for ordering from Sanofi Pasteur until mid-2018, when their new manufacturing facility is expected to be completed. However, YF-VAX might be available at some clinic...

OBJECTIVES To assess the relation between the number of clinical trials conducted and respective new drug approvals in India and South Africa. DESIGN Construction and analysis of a comprehensive database of completed randomised controlled clinical trials based on clinicaltrials.gov from 1 January 2005 to 31 December 2010 and drug approval data from 2006 until 2013 for India and South Africa. ...

In spite of the expenditure of many billions of dollars, cancer will soon become the major cause of human death other than aging [1]. Much of the funding allocated to cancer research has merely sustained the vested interests of those promoting the use of chemotherapeutic drugs designed to selectively kill cancer cells [2]. Incremental advances in understanding the biochemistry of cancer cells a...

Cancer immunotherapy is a relatively new and promising method of treating neoplasms. Understanding the antigen-directed cytotoxicity T-lymphocytes has become one central directions in involving immune system fight against cancer. Basic research this area led to invention checkpoint inhibitors, adoptive T-cell therapy, cancer vaccines. Cytokines can enhance action for their ability directly stim...

Cancer patients are more susceptible to adverse drug-drug interactions (DDIs) due to receiving multiple medications especially chemotherapy medications, hormonal agents and supportive care drugs. The aim of this study is to describe the prevalence of potential DDIs and to identify risk factors for these potential interactions in hospitalized cancer patients in a developing country.A cross-secti...

Cancer patients are more susceptible to adverse drug-drug interactions (DDIs) due to receiving multiple medications especially chemotherapy medications, hormonal agents and supportive care drugs. The aim of this study is to describe the prevalence of potential DDIs and to identify risk factors for these potential interactions in hospitalized cancer patients in a developing country.A cross-secti...

This study attempts to determine the extent to which new cancer drugs introduced during the last 40 years have prolonged the lives of Americans diagnosed with cancer. We use a difference-in-differences approach:we analyze the correlation across cancer sites (breast, prostate, lung, etc.) between changes in the hazard rate of people previously diagnosed with that cancer and changes in the number...